Roche Holding AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer
Phase 3
Completed
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 316
- Registration Number
- NCT02563054
A Non-interventional Functional Magnetic Resonance Imaging (fMRI) Study and Behavioral Assessment in Healthy Participants
Completed
- Conditions
- Healthy Volunteer
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 31
- Registration Number
- NCT02560142
- Locations
- π³π±
PRA Health Sciences Early Development Services, Zuidlaren, Netherlands
A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1035
- Registration Number
- NCT02560974
A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT02561039
An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: Peginterferon alfa-2aDrug: Ribavirin
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 697
- Registration Number
- NCT02557646
A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Biological: RO6874813
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 120
- Registration Number
- NCT02558140
- Locations
- πΊπΈ
SCRI, Nashville, Tennessee, United States
πͺπΈHospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain
πͺπΈSTART Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain
A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 270
- Registration Number
- NCT02556307
An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat)
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 442
- Registration Number
- NCT02553850
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT02554942
A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants
Phase 4
Completed
- Conditions
- Heart Transplantation
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT02554955
Β© Copyright 2025. All Rights Reserved by MedPath